Article Information
History
- January 3, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Roger M. Lane, MD1,*,
- Taher Darreh-Shori, PhD2,
- Candice Junge, PhD1,
- Dan Li, PhD1,
- Qingqing Yang, PhD1,
- Amanda L. Edwards, PhD3,
- Danielle L. Graham, PhD3,
- Katrina Moore, PhD1 and
- Catherine J. Mummery, MD4
- 1Ionis Pharmaceuticals, Carlsbad, CA, USA
- 2Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatric, Stockholm, Sweden
- 3Biogen, Cambridge, MA, USA
- 4Dementia Research Centre, Institute of Neurology, London, UK
- ↵*Corresponding author: Roger M. Lane, MD, MPH, Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA (rlane{at}ionisph.com)
Posted January 03, 2024.
Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
